Georgia Touts Its Medicaid Experiment as a Success. The Numbers Tell a Different Story.

Taxpayers and charities helped develop Zolgensma. Then it debuted at a record price, ushering in a new class of wildly expensive drugs. Its story upends the widely held conception that high prices reflect huge industry investments in innovation.

This article was produced for ProPublica’s Local Reporting Network in partnership with The Current. Sign up for Dispatches to get stories like this one as soon as they are published.

Reporting Highlights

  • Price of Independence: Georgia’s experimental alternative to Medicaid expansion has cost taxpayers more than $86 million.
  • Enrollment Shortfall: Only 6,500 participants have enrolled in the first 18 months of the program — roughly 75% fewer than the state had estimated for year one.
  • Work Slowdown: The state found it difficult to verify that people are working to keep their benefits, so Georgia has gone from monthly checks to annual ones.

These highlights were written by the reporters and editors who worked on this story.

// When Iterate loads, add a "Give Feedback" button to the page that, when clicked, opens a survey. Since Iterate is commonly blocked by ad blockers, we want to avoid displaying a feedback button that won't trigger a survey and will appear broken. document.addEventListener("DOMContentLoaded", (event) => { Iterate('onLoad', (survey) => { var elSurveyPlaceholder = document.getElementById("survey-placeholder"); elSurveyPlaceholder.innerHTML = "
 0
 0